Nationwide Fund Advisors grew its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 2.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 287,872 shares of the biotechnology company’s stock after acquiring an additional 7,478 shares during the period. Nationwide Fund Advisors owned 0.19% of Ironwood Pharmaceuticals worth $4,540,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Ameriprise Financial Inc. bought a new stake in Ironwood Pharmaceuticals in the second quarter worth $1,472,000. Oppenheimer Asset Management Inc. boosted its holdings in Ironwood Pharmaceuticals by 592.1% in the second quarter. Oppenheimer Asset Management Inc. now owns 17,878 shares of the biotechnology company’s stock worth $338,000 after purchasing an additional 15,295 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Ironwood Pharmaceuticals by 281.9% in the second quarter. Russell Investments Group Ltd. now owns 101,676 shares of the biotechnology company’s stock worth $1,920,000 after purchasing an additional 75,055 shares in the last quarter. State of Wisconsin Investment Board boosted its holdings in Ironwood Pharmaceuticals by 148.4% in the second quarter. State of Wisconsin Investment Board now owns 621,000 shares of the biotechnology company’s stock worth $11,724,000 after purchasing an additional 371,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Ironwood Pharmaceuticals by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 104,571 shares of the biotechnology company’s stock worth $1,974,000 after purchasing an additional 3,681 shares in the last quarter.

IRWD has been the subject of a number of recent research reports. BidaskClub upgraded shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. ValuEngine cut shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Credit Suisse Group initiated coverage on shares of Ironwood Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 price objective for the company. Cowen set a $20.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 21st. Finally, Mizuho reiterated a “buy” rating and issued a $20.00 price objective (down from $23.00) on shares of Ironwood Pharmaceuticals in a report on Friday, August 25th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average price target of $17.88.

Ironwood Pharmaceuticals, Inc. (IRWD) opened at $15.21 on Friday. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31. Ironwood Pharmaceuticals, Inc. has a 52-week low of $13.43 and a 52-week high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million during the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The business’s revenue was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.18) EPS. equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post -1.12 earnings per share for the current fiscal year.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the completion of the transaction, the chief executive officer now owns 4,696,917 shares of the company’s stock, valued at approximately $71,017,385.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 115,769 shares of company stock valued at $1,752,491. Company insiders own 7.63% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/12/15/ironwood-pharmaceuticals-inc-irwd-shares-bought-by-nationwide-fund-advisors.html.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.